CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima

Journal of Clinical Investigation

Volumn 119, Issue 1, 2009, Pages 136-145

  Young, Mi Park ^a,b   Febbraio, Maria ^a   Silverstein, Roy L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTIOXIDANT; CD36 ANTIGEN; CYSTEINE; FOCAL ADHESION KINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP; PROTEIN TYROSINE PHOSPHATASE SHP 2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; CYTOSKELETON; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MACROPHAGE MIGRATION; MONOCYTE; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CELL MOTION; CYTOLOGY; GENETICS; INTIMA; METABOLISM; PATHOLOGY; PERITONEUM MACROPHAGE; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD36; CELL MOVEMENT; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MICE; REACTIVE OXYGEN SPECIES; TUNICA INTIMA;

EID: 61749103652     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35535     Document Type: Article

References (55)

1. Murray, C.J., and Lopez, A.D. 1997. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 349:1436-1442.
2. Lusis, A.J. 2000. Atherosclerosis. Nature. 407:233-241.
3. Libby, P. 2002. Inflammation in atherosclerosis. Nature. 420:868-874.
4. Platt, N., and Gordon, S. 2001. Is the class A macrophage scavenger receptor (SR-A) multifunctional? - the mouse's tale. J. Clin. Invest. 108:649-654.
5. Silverstein, R.L., and Febbraio, M. 2000. CD36 and atherosclerosis. Curr. Opin. Lipidol. 11:483-491.
6. Angeli, V., et al. 2004. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity. 21:561-574.
7. Pentikainen, M.O., Oksjoki, R., Oorni, K., and Kovanen, P.T. 2002. Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. Arterioscler. Thromb. Vasc. Biol. 22:211-217.
8. Watanabe, N., and Ikeda, U. 2004. Matrix metalloproteinases and atherosclerosis. Curr. Atheroscler. Rep. 6:112-120.
9. Taubman, M.B., et al. 1997. Tissue factor in the pathogenesis of atherosclerosis. Thromb. Haemost. 78:200-204.
10. Daoud, A.S., Jarmolych, J., Augustyn, J.M., and Fritz, K.E. 1981. Sequential morphologic studies of regression of advanced atherosclerosis. Arch. Pathol. Lab. Med. 105:233-239.
11. Llodra, J., et al. 2004. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. U. S. A. 101:11779-11784.
12. Febbraio, M., et al. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:1049-1056.
13. Guy, E., Kuchibhotla, S., Silverstein, R.L., and Febbraio, M. 2007. Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36°/apoE° mice. Atherosclerosis. 192:123-130.
14. Kuchibhotla, S., et al. 2008. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc. Res. 78:185-196.
15. Febbraio, M., Guy, E., and Silverstein, R.L. 2004. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:2333-2338.
16. Rahaman, S.O., et al. 2006. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 4:211-221.
17. Moore, K.J., et al. 2002. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 277:47373- 47379.
18. Cao, C., Lawrence, D.A., Strickland, D.K., and Zhang, L. 2005. A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood. 106:3234-3241.
19. Podrez, E.A., et al. 2000. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105:1095-1108.
20. Dawson, D.W., et al. 1997. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell. Biol. 138:707-717.
21. Simantov, R., and Silverstein, R.L. 2003. CD36: a critical anti-angiogenic receptor. Front. Biosci. 8:s874-s882.
22. Stossel, T.P. 1994. The machinery of cell crawling. Sci. Am. 271:54-63.
23. Small, J.V., Stradal, T., Vignal, E., and Rottner, K. 2002. The lamellipodium: where motility begins. Trends Cell. Biol. 12:112-120.
24. Calalb, M.B., Polte, T.R., and Hanks, S.K. 1995. Tyrosine phosphorylation of Focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol. Cell. Biol. 15:954-963.
25. Orr, A.W., Pallero, M.A., Xiong, W.C., and Murphy-Ullrich, J.E. 2004. Thrombospondin induces RhoA inactivation through FAK-dependent signaling to stimulate focal adhesion disassembly. J. Biol. Chem. 279:48983- 48992.
26. Yu, D., Qu, C.K., Henegariu, O., Lu, X., and Feng, G.S. 1998. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem. 273:21125-21131.
27. Lu, W., Gong, D., Bar-Sagi, D., and Cole, P.A. 2001. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell. 8:759-769.
28. Wu, R.F., and Terada, L.S. 2006. Oxidative modification of protein tyrosine phosphatases. Sci. STKE. 2006:pl2.
29. Meng, T.C., Fukada, T., and Tonks, N.K. 2002. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell. 9:387-399.
30. Wissler, R.W., and Vesselinovitch, D. 1976. Studies of regression of advanced atherosclerosis in experimental animals and man. Ann. N. Y. Acad. Sci. 275:363-378.
31. Malinow, M.R. 1983. Experimental models of atherosclerosis regression. Atherosclerosis. 48:105-118.
32. Reis, E.D., et al. 2001. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J. Vasc. Surg. 34:541-547.
33. Febbraio, M., Hajjar, D.P., and Silverstein, R.L. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108:785-791.
34. Endemann, G., et al. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:11811-11816.
35. Podrez, E.A., Schmitt, D., Hoff, H.F., and Hazen, S.L. 1999. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103:1547-1560.
36. Nozaki, S., et al. 1995. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J. Clin. Invest. 96:1859-1865.
37. Podrez, E.A., et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277:38517-38523.
38. Kunjathoor, V.V., et al. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277:49982-49988.
39. Zhao, A., et al. 2005. Low-density lipoprotein from apolipoprotein E-deficient mice induces macrophage lipid accumulation in a CD36 and scavenger receptor class A-dependent manner. Arterioscler. Thromb. Vasc. Biol. 25:168-173.
40. Marleau, S., et al. 2005. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 19:1869-1871.
41. Jimenez, B., et al. 2000. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6:41-48.
42. Podrez, E.A., et al. 2007. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13:1086-1095.
43. Huang, M.M., Bolen, J.B., Barnwell, J.W., Shattil, S.J., and Brugge, J.S. 1991. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc. Natl. Acad. Sci. U. S. A. 88:7844-7848.
44. Miao, W., Vasile, E., Lane, W.S., and Lawler, J. 2001. CD36 associates with CD9 and integrins on human blood platelets. Blood. 97:1689-1696.
45. Bamberger, M.E., Harris, M.E., McDonald, D.R., Husemann, J., and Landreth, G.E. 2003. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 23:2665-2674.
46. Lee, S.R., Kwon, K.S., Kim, S.R., Rhee, S.G. 1998. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 273:15366-15372.
47. Chiarugi, P., et al. 2001. Two vicinal cysteines confer a peculiar redox regulation to low molecular weight protein tyrosine phosphatase in response to platelet-derived growth factor receptor stimulation. J. Biol. Chem. 276:33478-33487.
48. Kwon, J., et al. 2004. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. U. S. A. 101:16419-16424.
49. Kwon, J., Qu, C.K., Maeng, J.S., Falahati, R., Lee, C., and Williams, M.S. 2005. Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP. EMBO J. 24:2331-2341.
50. Matsumoto, K., Matsumoto, K., Nakamura, T., and Kramer, R.H. 1994. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 269:31807-31813.
51. Manes, S., et al. 1999. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol. Cell Biol. 19:3125-3135.
52. Bjorkhem, I., et al. 1991. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 11:15-22.
53. Rimm, E.B., et al. 1993. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 328:1450-1456.
54. Hatch, F.T. 1968. Practical methods for plasma lipoprotein analysis. Adv. Lipid Res. 6:1-68.
55. Febbraio, M., et al. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274:19055-19062.